Bio-Rad Laboratories, Inc. $BIO Shares Purchased by Natixis Advisors LLC

Natixis Advisors LLC grew its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 67.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 65,069 shares of the medical research company’s stock after purchasing an additional 26,119 shares during the quarter. Natixis Advisors LLC owned 0.24% of Bio-Rad Laboratories worth $18,245,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of BIO. Norges Bank bought a new position in Bio-Rad Laboratories during the second quarter valued at about $30,987,000. Ilex Capital Partners UK LLP raised its position in Bio-Rad Laboratories by 1,790.3% in the second quarter. Ilex Capital Partners UK LLP now owns 120,885 shares of the medical research company’s stock worth $29,172,000 after acquiring an additional 114,490 shares in the last quarter. Boston Trust Walden Corp bought a new stake in Bio-Rad Laboratories in the third quarter worth about $26,763,000. Scopia Capital Management LP acquired a new stake in Bio-Rad Laboratories in the 2nd quarter valued at about $22,862,000. Finally, Ariel Investments LLC boosted its position in shares of Bio-Rad Laboratories by 13.0% during the 2nd quarter. Ariel Investments LLC now owns 818,624 shares of the medical research company’s stock valued at $197,550,000 after purchasing an additional 93,964 shares in the last quarter. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Price Performance

Shares of Bio-Rad Laboratories stock opened at $269.95 on Thursday. The stock has a market capitalization of $7.29 billion, a price-to-earnings ratio of 9.67 and a beta of 1.18. The firm’s 50-day moving average price is $293.75 and its two-hundred day moving average price is $300.72. The company has a current ratio of 5.62, a quick ratio of 4.19 and a debt-to-equity ratio of 0.16. Bio-Rad Laboratories, Inc. has a 1-year low of $211.43 and a 1-year high of $343.12.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, February 12th. The medical research company reported $2.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.06). The firm had revenue of $693.20 million during the quarter, compared to the consensus estimate of $694.64 million. Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. The business’s revenue was up 3.9% on a year-over-year basis. During the same quarter last year, the firm posted $2.90 EPS. On average, equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on BIO shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research note on Monday, December 29th. Wall Street Zen cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Bio-Rad Laboratories presently has an average rating of “Hold” and an average target price of $358.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.